Physician profile
Benjamin J Workman
NPI 1568751931
$283,806.67
in general payments reported to CMS, 2019-2025
34 companies · $71K in 2025
The $71K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $9,218 · 2021: $20K · 2022: $46K · 2023: $55K · 2024: $60K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $164K · Food and Beverage: $12K · Travel and Lodging: $5,959 · Consulting Fee: $3,100 · Education: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $164,179.50 |
| Food and Beverage | $11,721.66 |
| Travel and Lodging | $5,959.27 |
| Consulting Fee | $3,100.00 |
| Education | $690.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $109,877.59 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Janssen Scientific Affairs, LLC | $78,267.38 | 2019-2022 | |
| Genzyme Corporation | $76,288.61 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,615.00 | 2022-2025 | Spevigo, Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $2,821.69 | 2019-2024 | Siliq, Targretin |
| Abbvie INC. | $2,597.34 | 2019-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $1,741.22 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $1,677.94 | 2019-2025 | |
| Ucb, INC. | $1,080.15 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $848.30 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $785.13 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $683.07 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $520.71 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $472.10 | 2021-2025 | Sotyktu |
| Pfizer INC. | $448.68 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $420.38 | 2019-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $230.08 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $226.91 | 2019-2025 | Nemluvio, Aklief |
| Celgene Corporation | $186.79 | 2019 | |
| Biofrontera INC. | $173.91 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Sandoz INC. | $136.46 | 2019-2023 | Hyrimoz |
| Dermavant Sciences, INC. | $118.16 | 2023-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Journey Medical Corporation | $91.35 | 2021-2024 | |
| Organon LLC | $81.69 | 2023-2025 | Hadlima, Vtama |
| Genentech USA, INC. | $75.59 | 2022-2023 | Xolair |
| Vyne Pharmaceuticals INC. | $57.16 | 2021 | |
| Paratek Pharmaceuticals, INC. | $54.90 | 2022-2023 | Nuzyra |
| Dermira, INC. | $37.05 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $24.82 | 2023 | Idacio |
| Almirall LLC | $22.42 | 2023 | Seysara |
| Prugen, INC. Pharmaceuticals | $17.42 | 2020 | |
| Verrica Pharmaceuticals INC. | $13.51 | 2023 | Ycanth |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Workman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.